Immunisation references

  1. Plotkin, S.A., Orenstein, W.A., and Offit, P.A. eds. (2007). Vaccine. 5th edition. Saunders Elsevier.
  2. Lemon, S.M., and Thomas D.L. (1997) Vaccines to prevent viral hepatitis. N Engl J Med 336 (3), 196–204.
  3. Neuzil, K.M., et al. (2001) Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 20 (8), 733–40.
  4. Roush, S.W., and Murphy, T.V. (2007) Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 298 (18), 2155–63.
  5. Simons, E., et al. (2012) Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet 379 (9832), 2173–8.
  6. Zhang, L., et al. (2012) Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev 3, CD001478.
  7. Institute of Medicine. (2012) Adverse effects of vaccines: evidence and causality. Washington, D.C.: The National Academies Press.
  8. Barlow, W.E., et al. (2001) The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 345 (9), 656–61.
  9. Mantadakis, E., Farmaki E., and Buchanan, G.R. (2010) Thrombocytopenic purpura after measles–mumps–rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr 156 (4), 623–8.
  10. Perry, R.T., and Halsey, N.A. (2004) The clinical significance of measles: a review. J Infect Dis 189 Suppl 1: S4–16.
  11. Pulendran, B., and Ahmed, R. 2011 Immunological mechanisms of vaccination. Nat Immunol 12 (6), 509–17.
  12. Stowe, J., et al. (2009) Investigation of the temporal association of Guillain–Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol 169(3), 382–8.
  13. Wraith, D.C., Goldman, M. and Lambert, P.H. (2003) Vaccination and autoimmune disease: what is the evidence? Lancet 362 (9396), 1659–66.
  14. Alberts, B., et al. (2007) Molecular Biology of the Cell. 5th edition. New York: Garland Science.
  15. Murphy, K., Travers, P., and Walport, M. (2007) Janeway’s Immunobiology. 7th edition. Garland Science: 928.
  16. Banchereau, J., and Steinman, R.M. (1998) Dendritic cells and the control of immunity. Nature 392 (6673), 245–52.
  17. Gowans, J.L., McGregor, D.D., and Cowen, D.M. (1962) Initiation of immune responses by small lymphocytes. Nature 196: 651–5.
  18. Miller, J.F. (1961) Immunological function of the thymus. Lancet 2 (7205), 748–9.
  19. Miller, J.F. and Mitchell, G.F. (1968) Cell to cell interaction in the immune response. I. Hemolysin- forming cells in neonatally thymectomized mice reconstituted with thymus or thoracic duct lymphocytes. J Exp Med 128 (4), 801–20.
  20. Roitt, I.M., et al. (1969) The cellular basis of immunological responses. A synthesis of some current views. Lancet 2 (7616), 367–71.
  21. Zinkernagel, R.M., and Doherty, P.C. (1974) Restriction of in vitro T-cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248 (450), 701–2.
  22. Burnet, F.M. (1959) The Clonal Selection Theory of Acquired Immunity. London: Cambridge University Press.
  23. Ahmed, R., and Gray, D. (1996) Immunological memory and protective immunity: understanding their relation. Science, 272 (5258), 54–60.
  24. Sallusto, F., et al. (2010) From vaccines to memory and back. Immunity 33 (4), 451–63.
  25. Panum, P.L. (1847) Observations made during the epidemic of measles on the Faroe Islands in the year 1846. Bibiliothek for Laeger, Copenhagen, 3R 1, 270–344.
  26. Adkins, B., Leclerc, C. and Marshall-Clarke, S. (2004) Neonatal adaptive immunity comes of age. Nat Rev Immunol 4 (7), 553–64.
  27. Thucydides. The History of the Peloponnesian War. Everyman’s Library (1910), London: J. M. Dent Ltd.
  28. Hopkins, D.R. (2002) The Greatest Killer: Smallpox in History. Chicago: The University of Chicago Press.
  29. Montagu, M.W. (1796) Letter 36 to Mrs SC from Adrianople. Letters of the Right Honourable Lady Written during her travels in Europe, Asia and Africa. Aix. Anthony Henricy. 1: 167–169.
  30. Jenner, E. (1798) An Enquiry Into the Causes and Effects of the Variolae Vaccinae or Cow-pox. Harvard Classics, New York: P.F. Collier & Son.
  31. Fenner, F. (1999) Nature, nurture and my experience with smallpox eradication. Med J Aust 171 (11–12), 638–41.
  32. World Health Organisation. (2009) Hepatitis B vaccines. Wkly Epidemiol Rec 84 (40), 405–19.
  33. Ascherio, A., et al. (2001) Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 344 (5), 327–32.
  34. Karvonen, M., Cepaitis, Z. and Tuomilehto, J. (1999) Association between type 1 diabetes and Haemophilus influenzae type b vaccination: birth cohort study. BMJ 318 (7192), 1169–72.
  35. No authors listed. (2002) Hepatitis B vaccine and demyelinating neurological disorders. Immunisation Safety Review. Washington D.C.: The National Academies Press.
  36. Bach, J.F. (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347 (12), 911–20.
  37. Chen, R.T., Pless, R. and Destefano, F. (2001) Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun 16 (3), 309–18.
  38. Rose, N.R., and Mackay, I.R. (2006) The Autoimmune Diseases. 4th edition. London: Elsevier Academic Press.
  39. Chen, R.T., et al. (1990) Measles antibody: reevaluation of protective titers. J Infect Dis 162 (5), 1036–42.
  40. Schauer, U., et al. (2003) Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults. Clin Diagn Lab Immunol 10 (2), 202–7.
  41. Weibel, R.E., et al. (1967) Live attenuated mumps-virus vaccine. 3. Clinical and serologic aspects in a field evaluation. N Engl J Med 276 (5), 245–51.
  42. Delrue, I., et al. (2012) Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges. Expert Rev Vaccines 11 (6), 695–719.
  43. Dull, P.M., and McIntosh, E.D. (2012) Meningococcal vaccine development – from glycoconjugates against MenACWY to proteins against MenB – potential for broad protection against meningococcal disease. Vaccine 30 Suppl 2: B18–25.
  44. Parkman, P.D., and Hopps, H.E. (1988) Viral vaccines and antivirals: current use and future prospects. Annu Rev Public Health 9: 203–21.
  45. Zuckerman, A.J. (1985) Subunit, recombinant and synthetic hepatitis B vaccines. Scand J Gastroenterol Suppl 117: 27–38.
  46. Avci, F.Y., et al. (2011) A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med 17 (12), 1602–9.
  47. Englund, J.A., et al. (1993) Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. J Infect Dis 168 (3), 647–56.
  48. Lauring, A.S., Jones, J.O. and Andino, R. (2010) Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol 28 (6), 573–9.
  49. Edelman, R. (1980) Vaccine adjuvants. Rev Infect Dis 2 (3), 370–83.
  50. Einstein, M.H., et al. (2009) Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin 5 (10), 705–19.
  51. Faretra Peysson, L. (2010) Tracing and control of raw materials sourcing for vaccine manufacturers. Biologicals 38 (3), 352–3.
  52. Bohlke, K., et al. (2003) Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 112 (4), 815–20.
  53. Hurley, A.M., Tadrous, M., and Miller, E.S. (2010) Thimerosal-containing vaccines and autism: a review of recent epidemiologic studies. J Pediatr Pharmacol Ther 15 (3), 173–81.
  54. Offit, P.A. and Jew, R.K. (2003) Addressing parents’ concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics 112 (6 Pt 1), 1394–7.
  55. Imafidon, G.I. and Sosulski, F.W. (1990) Nucleic acid nitrogen of animal and plant foods. J Agric Food Chem 38 (1), 118–120.
  56. Ghosh, S., et al. (2001) Detection of persistent measles virus infection in Crohn’s disease: current status of experimental work. Gut 48 (6), 748–52.
  57. Khakoo, G.A. and Lack, G. (2000) Recommendations for using MMR vaccine in children allergic to eggs. BMJ 320 (7239), 929–32.
  58. Mullins, R.J., Kemp, A. and Gold, M. (2010) Influenza vaccination of the egg-allergic individual. Med J Aust 193 (5), 254–5.
  59. DiMiceli, L., et al. (2006) Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine 24 (6), 703–7.
  60. Campbell, H., et al., Review of the effect of measles vaccination on the epidemiology of SSPE. Int J Epidemiol, 2007. 36 (6), 1334–48.
  61. Nebbia, G., Peppa, D. and Maini, M.K. (2012) Hepatitis B infection: current concepts and future challenges. QJM 105 (2), 109–13.
  62. Pol, S., et al. (2012) Hepatitis C: epidemiology, diagnosis, natural history and therapy. Contrib Nephrol 176, 1–9.
  63. El-Serag, H.B. (2011) Hepatocellular carcinoma. N Engl J Med 365 (12), 1118–27.
  64. McLaughlin-Drubin, M.E., Meyers, J., and Munger, K. 2012 Cancer associated human papillomaviruses. Curr Opin Virol 2 (4), 459–66.
  65. Schiffman, M., et al. (2007) Human papillomavirus and cervical cancer. Lancet 370 (9590), 890–907.
  66. Kahn, J.A. (2009) HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med 361 (3), 271–8.
  67. Kimberlin, D.W., and Whitley, R.J. (2007) Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 356 (13), 1338–43.
  68. Kim, T.H., Johnstone, J. and Loeb, M. (2011) Vaccine herd effect. Scand J Infect Dis 43 (9), 683–9.
  69. Davidkin, I., et al. (2010) MMR vaccination and disease elimination: the Finnish experience. Expert Rev Vaccines 9 (9), 1045–53.
  70. Simonsen, L., et al. (2011) Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio 2 (1), e00309–10.
  71. Centres for Disease Control and Prevention. (2012) Progress toward interruption of wild poliovirus transmission – worldwide, January 2011 – March 2012. MMWR Morb Mortal Wkly Rep 61 (19), 353–7.
  72. Kahn, C.R. (1989) Perverted priorities. The physician/scientist as spokesman and salesman for biomedical research. Presidential address to the American Society for Clinical Investigation, Washington, DC, 29 April 1989. J Clin Invest 84 (3), 723–7.
  73. Beyer, W.E., et al. (1996) Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. Eur J Clin Microbiol Infect Dis 15 (1), 65–70.
  74. Peltola, H., and Heinonen, O.P. (1986) Frequency of true adverse reactions to measles– mumps–rubella vaccine. A double-blind placebo- controlled trial in twins. Lancet 1 (8487), 939–42.
  75. Klein N.P., et al. (2010) Measles-mumps- rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 126 (1), e1–8.
  76. Poehling, K.A., et al. (2006) The underrecognized burden of influenza in young children. N Engl J Med 355 (1), 31–40.
  77. Parker, S.K., et al. (2004) Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics 114 (3), 793–804.
  78. Koppen, S., et al. (2004) No epidemiological evidence for infant vaccinations to cause allergic disease. Vaccine 22 (25–26), 3375–85.
  79. Brotherton, J.M., et al. (2008) Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 179 (6), 525–33.
  80. Centres for Disease Control and Prevention. (2011) General recommendations on immunization – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60 (2), 1–64.
  81. Sheffield, J.S., et al. (2012) Effect of influenza vaccination in the first trimester of pregnancy. Obstet Gynecol 120 (3), 532–7.
  82. Tamma, P.D., Steinhoff, M.C. and Omer, S.B. (2010) Influenza infection and vaccination in pregnant women. Expert Rev Respir Med 4 (3), 321–8.
  83. Moro, P.L., et al. (2011) Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990–2009. Am J Obstet Gynecol 204 (2), 146 e1–7.
  84. Offit, P.A. (2005) The Cutter incident, 50 years later. N Engl J Med 352 (14), 1411–2.
  85. White, O.J., et al. (2012) A genomics-based approach to assessment of vaccine safety and immunogenicity in children. Vaccine 30 (10), 1865–74.
  86. Mahajan D., Campbell-Lloyd S., Cook J., Menzies R.I. (2011) NSW annual report describing adverse events following immunisation, 2010. N S W Public Health Bull 22 (9–10), 196–208.
  87. Lasky, T., et al. (1998) The Guillain–Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med 339 (25), 1797–802.
  88. Murphy, T.V., et al. (2001) Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 344 (8), 564–72.
  89. Rennels, M.B., et al. (1998) Lack of an apparent association between intussusception and wild or vaccine rotavirus infection. Pediatr Infect Dis J 17 (10), 924–5.
  90. Buttery, J.P., et al. (2011) Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in Australia. Vaccine 29 (16), 3061–3066.
  91. Dey, A., et al. (2012) Changes in hospitalisations for acute gastroenteritis in Australia following the national rotavirus vaccination program. Med J Aust 197 (8), 453–7.
  92. World Health Organisation. (2012) Rotavirus vaccines and intussusception. Wkly Epidemiol Rec 87 (6), 53–60.
  93. Rappuoli, R., et al. (2011) Vaccines for the twenty-first century society. Nat Rev Immunol 11 (12), 865–72.
  94. No authors listed. (2011) World Health Statistics 2011. France: World Health Organisation.
  95. Li, N., et al. (2011) Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers. Vaccine 29 (37), 6179–90.
  96. van der Maaden, K., Jiskoot, W., and Bouwstra, J. (2012) Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release 161 (2), 645–55.
  97. Mbow, M.L., et al. (2010) New adjuvants for human vaccines. Curr Opin Immunol 22 (3), 411–6.
  98. Rybicki, E.P. (2009) Plant-produced vaccines: promise and reality. Drug Discov Today 14 (1–2), 16–24.
  99. Garland, S.M., et al. (2007) Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines. Clin Vaccine Immunol 14 (6), 792–5.
  100. Weibel, R.E., et al. (1975) Long-term follow- up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines. Pediatrics 56 (3), 380–7.
  101. Rappuoli, R., and Aderem, A. (2011) A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473 (7348), p. 463–9.
  102. de Martel, C., et al., (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13 (6), 607–15.
  103. Frazer, I. (2006) God’s gift to women: the human papillomavirus vaccine. Immunity 25 (2), 179–84.
  104. Rupnow, M.F., et al. (2009) Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. J Infect Dis 200 (8), 1311–7.
  105. Howie, S.E., et al. (2011) Immunity and vaccines against sexually transmitted Chlamydia trachomatis infection. Curr Opin Infect Dis 24 (1), 56–61.
  106. Nossal, G.J. (2011) Vaccines of the future. Vaccine 29 Suppl 4: D111–5.

© 2017 Australian Academy of Science

Top